INSIGHTS ON DRUG DEVELOPMENT

• S.U.B. Enhancements For High-Density Perfusion Cultures

  This study presents how strategic enhancements to the sparge and agitation systems of Thermo Scientific HyPerforma S.U.B.s have revealed the potential for a three- to four-fold improvement in mixing and mass transfer performance compared to legacy S.U.B. designs.

• Key Considerations For A Successful EU Orphan Drug Launch

  During this interactive webinar, the speakers involved will utilize their experience to guide you through the EU product launch process, from submitting your Marketing Application (MA) to final distribution of drug product to the end-user.

• Optimizing Process Efficiency In Upstream Manufacturing

  Increasing the integration of upstream and downstream processing and moving toward increased automation results in greater optimization of process efficiency — a key goal for biopharma production.

• Single-Use Platforms Accelerate Viral Vaccine Development And Manufacturing

  Biopharma analysts predict the market for vaccines could grow at a compound annual growth rate of as much as 10.3 percent through 2024. Single-use platforms that eliminate reinvention of the wheel for each candidate might be pivotal to meeting that demand.

• Create Brand Sustainability With Softgel Technology

  Keeping an eye on some emerging trends that are shaping society and the pharmaceutical industry can help you meet diverse consumer preferences and potentially extend product lifecycles.

• Delivering Macromolecules: Challenges Associated With The Delivery Of Biologic Drugs

  Developers need to look beyond the formulation of a stable drug all the way to patient compliance. Numerous pitfalls exist along the journey to bring a biologic combination product to market. This integrated solutions program can help you simplify the journey.

• Integrated Tools For Upstream Process Intensification: Part II

  Changes to bioprocessing methodologies in the biopharmaceutical industry are being driven by the need for increased speed, a lower cost of goods (COGs) and greater flexibility. Faster development times are required to progress biologics and vaccines more rapidly into clinical development and then to market to improve worldwide accessibility. Continue reading in part 2 of this series how in order for intensified and continuous bioprocessing to deliver on these quality and productivity promises, there is a requirement for intelligently designed products.

• Data Gathering And Analysis Necessary In New Tablet Development

  A significant concern in tablet manufacturing is speed to market. Moving too quickly, however, may cause delayed production, lost product, and missed deadlines. To reduce potential headaches, companies are embracing the principles of Quality by Design (QbD) and utilizing automated data gathering and tablet analysis during research and development. This allows organizations to reduce product development and delivery stress and loss.

• Optimizing Cell Culture Media To Increase Cell Culture Titer With Maintained Protein Quality

  When evaluating media with the goal of increasing titers, it is important to ensure that protein quality is not negatively impacted. So how can this process improvement be performed reliably? It makes sense to use a Design of Experiments (DoE) and empirical approach. Here is an example of how to do it.